<?xml version="1.0" encoding="UTF-8"?>
<p>Considering the imperative need to find an effective treatment against SARS-CoV-2 infection (which is lacking at present), administration of immune “convalescent” sera containing neutralizing antibodies against SARS-CoV-2 was viewed as a viable approach, with rapid results by conferring immediate immunity to highly susceptible patients [
 <xref rid="B147-jcm-09-02084" ref-type="bibr">147</xref>,
 <xref rid="B148-jcm-09-02084" ref-type="bibr">148</xref>]. Convalescent serum/plasma exerts its highest efficacy if is administrated as prophylaxis or early after the onset of the clinical symptoms [
 <xref rid="B147-jcm-09-02084" ref-type="bibr">147</xref>,
 <xref rid="B148-jcm-09-02084" ref-type="bibr">148</xref>]. The data regarding convalescent plasma administered as treatment in COVID-19 patients are rather scarce, and only several reports from China assert the efficacy of this kind of treatment (small size studies) characterized by an improvement of clinical outcome, decreased viral loads, and clinical stabilization [
 <xref rid="B147-jcm-09-02084" ref-type="bibr">147</xref>].
</p>
